A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

Completed · Phase 4 · Has a placebo group

Conditions studied: Herpes Simplex, HIV Infections

In brief

The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.

Key facts

Study ID

NCT00161434

Run by

University of Washington

People needed

60

Starts

2003-03-01

Expected to finish

2006-06-01

Last updated by the study team

2008-01-10

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• HIV seropositive and HSV-2 seropositive
• MSM (men having sex with men)
• 18 years old or older

You may not qualify if…

• Known history of adverse reaction to acyclovir or valacyclovir
• Planned open label use of acyclovir, valacyclovir or famciclovir

Where it is running

• Virology Research Clinic — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.